Evommune, Inc.
EVMN
$24.09
-$0.94-3.76%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 10.00M | 0.00 | 3.00M | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 10.00M | 0.00 | 3.00M | 0.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00 | 10.00M | 0.00 | 3.00M | 0.00 |
| SG&A Expenses | 9.31M | 3.69M | 3.36M | 3.67M | 3.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.72M | 23.33M | 22.99M | 18.03M | 21.45M |
| Operating Income | -29.72M | -13.33M | -22.99M | -15.03M | -21.45M |
| Income Before Tax | -28.27M | -12.48M | -13.57M | -14.56M | -20.73M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.27M | -12.48M | -13.57M | -14.56M | -20.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.27M | -12.48M | -13.57M | -14.56M | -20.73M |
| EBIT | -29.72M | -13.33M | -22.99M | -15.03M | -21.45M |
| EBITDA | -29.39M | -13.02M | -22.62M | -14.66M | -21.09M |
| EPS Basic | -1.43 | -8.07 | -8.80 | -9.48 | -14.54 |
| Normalized Basic EPS | -0.89 | -5.05 | -5.50 | -5.93 | -8.48 |
| EPS Diluted | -1.43 | -8.07 | -8.80 | -9.48 | -14.54 |
| Normalized Diluted EPS | -0.89 | -5.05 | -5.50 | -5.93 | -8.48 |
| Average Basic Shares Outstanding | 19.78M | 1.55M | 1.54M | 1.54M | 1.53M |
| Average Diluted Shares Outstanding | 19.78M | 1.55M | 1.54M | 1.54M | 1.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |